ResearcherUniversity of FloridaNo recent work listed

Weijing Cai

Provisional: name at one institution (moderate confidence, 0.60), identity_conf@1As of 8 November 2026

Known by name at one institution; no external author ID yet. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2019: 1 paper

Papers 1

Development of apratoxin S10 (Apra S10) as an anti-pancreatic cancer agent and its preliminary evaluation in an orthotopic patient-derived xenograft (PDX) mode… Co-author DOI 10.1007/s10637-018-0647-0 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Michael H. Gerber · 1 shared paper, 2019 · strength 0.10
- Paper Development of apratoxin S10 (Apra S10) as an anti-pancreatic cancer agent and its preliminary evaluation in an orthoto… DOI 10.1007/s10637-018-0647-0 ↗
Hendrik Luesch · 1 shared paper, 2019 · strength 0.10
- Paper Development of apratoxin S10 (Apra S10) as an anti-pancreatic cancer agent and its preliminary evaluation in an orthoto… DOI 10.1007/s10637-018-0647-0 ↗
Jose Gilberto Trevino · 1 shared paper, 2019 · strength 0.10
- Paper Development of apratoxin S10 (Apra S10) as an anti-pancreatic cancer agent and its preliminary evaluation in an orthoto… DOI 10.1007/s10637-018-0647-0 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.